If you have been reading about deamidation and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-07-12. Where a claim depends on a specific study, the study is described rather than over-claimed.
Research-grade material circulates through suppliers that differ widely in documentation and testing practice, so a certificate of analysis is a starting point rather than proof of quality. Independent verification typically repeats chromatographic purity and mass confirmation on the received lot, and compares results against a retained reference standard. Regulatory status varies by jurisdiction, and a substance cleared as a medicine is not interchangeable with a research chemical of the same name. Open questions include how closely non-pharmaceutical lots match approved material in impurity profile and in aggregate content.
Solid tirzepatide is handled as a lyophilised, hygroscopic peptide powder that should be kept desiccated, protected from light, and stored frozen, typically at or below minus twenty degrees Celsius for long-term retention. Material left at ambient temperature for extended periods can take up moisture, which promotes aggregation and deamidation. Commercial liquid presentations are kept refrigerated between two and eight degrees Celsius and are not frozen. Reconstituted laboratory solutions are generally held cold and used within a short window because hydrolysis and oxidation continue slowly in solution.
Identity and purity are usually established with reversed-phase high-performance liquid chromatography for the main peak and with mass spectrometry for the observed molecular mass. Peptide mapping after enzymatic digestion confirms the primary sequence, while amino acid analysis provides a quantitative composition check. Size-exclusion chromatography and ion-exchange chromatography are used to look for aggregates and charge variants. Water content, residual solvents, and counter-ion content are measured separately, since a lyophilised powder is often reported on an as-is basis unless a correction is applied.
Identity and purity are assessed by reversed-phase high-performance liquid chromatography, with mass confirmation by electrospray ionisation mass spectrometry. Peptide mapping after enzymatic digestion verifies the primary sequence. Size-exclusion chromatography quantifies aggregates, while circular dichroism provides a secondary-structure fingerprint. Bioanalytical quantification in plasma uses immunoassay or LC-MS/MS. Reported purity for research-grade lots is commonly 95 percent or higher, and residual water content is checked by Karl Fischer titration.
As a peptide, tirzepatide is handled as a lyophilised solid in research settings and as a preserved solution in finished products. Aqueous solubility is pH dependent and reaches a minimum near the isoelectric point, which lies close to pH 5.4. Stock solutions are typically prepared in neutral or slightly basic buffer to limit precipitation. The solid is hygroscopic and should be equilibrated to room temperature before opening so that condensation does not form on the powder surface.
Recommended storage for reference material is a freezer at approximately -20 degrees Celsius, protected from light and moisture. Commercial injectable presentations are stored refrigerated between 2 and 8 degrees Celsius and must not be frozen. Product labelling generally permits a limited period at controlled room temperature once dispensed, with the exact window depending on the presentation. Repeated temperature cycling is avoided because it can promote aggregation or deamidation of the peptide chain.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilised solid, may form a loose cake |
| Solubility class | Soluble in water | Practically insoluble in nonpolar solvents |
| Storage temperature, solid | -20 °C or below | Desiccated and protected from light |
| Storage temperature, liquid | 2-8 °C | Refrigerated, not frozen |
| Typical identity method | LC-MS | Observed mass compared with calculated mass |
Stability depends strongly on physical form. The dry powder is generally regarded as stable for extended periods when held at or below minus twenty degrees Celsius in a sealed, desiccated container. In solution, degradation pathways include deamidation of asparagine and glutamine residues, oxidation of methionine, and aggregation. Reaction rates for these pathways rise with temperature. Repeated freezing and thawing of solutions promotes aggregation, and light exposure can accelerate some oxidative changes. Buffer composition and pH influence which pathway dominates at a given temperature.
Regulatory and quality discussions place the peptide within established guidance for synthetic peptides and biologics. Forced degradation studies, in which samples are exposed to heat, acid, base, peroxide, and light, identify likely degradation products and validate the selectivity of analytical methods. Reference standards allow comparison across laboratories and production batches. Purity specifications reported in the literature usually combine chromatographic purity with mass confirmation. Which impurity thresholds are meaningful for long-term behavior is still debated, and no single universal specification has been adopted across all jurisdictions.
Routine characterization of the peptide relies on reversed-phase high-performance liquid chromatography for purity assessment, usually with ultraviolet detection near 214 nanometers. Intact mass measurement by liquid chromatography coupled to mass spectrometry confirms molecular identity against a theoretical value. Sequence-level confirmation uses enzymatic digestion followed by tandem mass spectrometry, an approach known as peptide mapping. Amino acid analysis gives an independent check on composition. Circular dichroism spectra are used to estimate helical content in aqueous buffer.
Characterization of the peptide relies on reversed-phase high-performance liquid chromatography for purity and related-substance profiling, with ultraviolet detection near 214 nanometers. Mass spectrometry confirms molecular mass and reveals modifications such as oxidation or deamidation. Peptide mapping after enzymatic digestion verifies the amino acid sequence, while amino acid analysis supplies compositional data. Circular dichroism and infrared spectroscopy are used to assess secondary structure, particularly the alpha-helical content that influences aggregation behavior in solution.
Common degradation routes include hydrolysis of labile amide bonds, deamidation of asparagine and glutamine residues, oxidation of methionine and tryptophan, and non-covalent aggregation. Aggregates can form during freeze-thaw cycling, at elevated pH, or when peptide concentration is high. Each route produces characteristic chromatographic or mass shifts that are tracked during stability studies. Whether a given minor impurity alters biological activity is often an open question, and specification limits are typically set on identity and purity rather than on functional data for trace species.
Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
Receptor activation by tirzepatide raises intracellular cyclic AMP through Gs-coupled signalling at both targets. At the GLP-1 receptor the downstream effect includes glucose-dependent insulin release, suppressed glucagon secretion, delayed gastric emptying, and reduced appetite signalling in the hypothalamus. GIP receptor engagement adds insulinotropic activity and appears to influence lipid handling in adipose tissue. Because both receptors are stimulated at the same time, the pharmacological profile differs from that of selective GLP-1 receptor agonists, and the relative contribution of each arm remains an area of active investigation.
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
=== ICD-11 === Anorexia nervosa is classified under feeding or eating disorders in both the ICD-11 and the DSM-5. Like the DSM-5, the ICD-11 also distinguishes between a binge-purge pattern and a restricting pattern with further subcodes.
The region is 1,200 kilometres (750 mi) from the sea and has an arid continental climate on the north to humid continental climate to the south, with average summer temperatures rising to 17 to 24 °C (63 to 75 °F) in July and average winter temperatures dropping to between −7 and −15 °C (19 and 5 °F) in January. Seasonal extreme temperatures can reach 39 °C (102 °F) in summer and −30 °C (−22 °F) in winter. The diurnal temperature variation can reach above 17 °C (31 °F), especially in spring. Annual rainfall averages from 190 to 700 millimetres (7.5 to 27.6 in), with more rain falling in the south of the region.
=== Fabrication === The electrostatic potential needed to create a quantum dot can be realized with several methods. These include external electrodes, doping, strain, or impurities. Self-assembled quantum dots are typically between 5 and 50 nm in size. Quantum dots defined by lithographically patterned gate electrodes, or by etching on two-dimensional electron gases in semiconductor heterostructures can have lateral dimensions between 20 and 100 nm. The formation of quantum dots can be spontaneous when a semiconductor material is deposited on a substrate and a difference in lattice space exists between them. By means of advanced nanofabrication technologies it is possible to manipulate properties of the quantum dots, such as their interactions, shape, size and transparency. For example, when negative voltage is applied to a metal gate around a QD, as response, its diameter starts to be gradually squeezed, as a consequence, the number of electrons on the dot starts to decrease one by one, this could be made until there are no more left. The previous property allows to record the current flow as the number of electrons on the dot, this implies that the energy variates.
Rui Pedro Teixeira Mendonça (born 28 January 1987) is a Portuguese boy who went missing on 4 March 1998 in Lousada, northern Portugal. Mendonça was 11 years old and riding his bicycle outside near his home when he disappeared. The subsequent police investigation was criticized by both the media and by the missing boy's family. Mendonça's whereabouts remain unknown, and he was declared legally dead in 2019.
==== Age-related myelin decline ==== Retrogenesis is a medical hypothesis that just as the fetus goes through a process of neurodevelopment beginning with neurulation and ending with myelination, the brains of people with Alzheimer's disease go through a reverse neurodegeneration process starting with demyelination and death of axons (white matter) and ending with the death of grey matter. Likewise the hypothesis is, that as infants go through states of cognitive development, people with Alzheimer's disease go through the reverse process of progressive cognitive impairment. According to one theory, dysfunction of oligodendrocytes and their associated myelin during aging contributes to axon damage, which in turn generates amyloid production and tau hyperphosphorylation. Comorbidities between the demyelinating disease, multiple sclerosis, and Alzheimer's disease have been reported.
Sources: en.wikipedia.org
Elevated creatine kinase (CK) levels in the blood (at most ~10 times normal) are typical in sIBM but affected individuals can also present with normal CK levels. Electromyography (EMG) studies display variable abnormalities such as increased insertional activity, increased spontaneous activity (fibrillation potentials and sharp waves), and large/broad or short/narrow motor unit potentials. On EMG, recruitment patterns can be reduced or increased. Findings can vary even within the same muscle of an affected individual. Muscle biopsy may display several common findings including inflammatory cells invading muscle cells, vacuolar degeneration, and inclusion bodies of aggregations of multiple proteins. sIBM is a challenge to the pathologist and even with a biopsy, diagnosis can be ambiguous. A diagnosis of inclusion body myositis was historically dependent on muscle biopsy results. Antibodies to cytoplasmic 5'-nucleotidase (cN1A; NT5C1A) have been strongly associated with the condition. However, other inflammatory conditions, such as lupus, can have a positive anti-NT5C1A. As of 2019, it remains to be established whether a positive anti-NT5C1A antibody test can make muscle biopsy unneeded.
=== Cardiac involvement === About 30% of MCTD patients have symptomatic heart disease, whereas up to 40% have subclinical cardiac illness. The most common ECG abnormalities are hemiblock, bundle branch block, and atrioventricular block. Pericarditis is the most common clinical indication of cardiac involvement, affecting up to 40% of patients.
Maximinus Thrax, Roman emperor (c. 173, reigned 235–238). Descriptions, as well as depictions, indicate acromegaly, though remains of his body are yet to be found. Lorenzo de' Medici (1449–1492) may have had acromegaly. Historical documents and portraits, as well as a later analysis of his skeleton, support the speculation. Sergei Rachmaninoff (1873–1943), pianist and composer, who was noted for his hands that could comfortably stretch a thirteenth on the piano. He was not diagnosed with acromegaly in his lifetime, but a medical article from 2006 suggests that he might have had it. Adam Rainer (22 February 1899 – 4 March 1950), Austrian man who is the only person in recorded history to have been both a dwarf and a giant. He is believed to have had acromegaly.[51]
== History == In October 1967, Techtron Pty Ltd merged with Varian Associates. Techtron is a manufacturer of Atomic Absorption Spectrometers and Spectral lamps. In 1982, Varian transferred the Cary UV-Visible product line to Australia. In 1997, Varian bought Chemagnetics, a Colorado-based manufacturer of solid-state NMR spectrometers. In 2002, Varian bought Ansys Technologies, Inc., a California-based manufacturer of In-Vitro Medical Devices. In 2004, Varian Inc bought Magnex Scientific, an Oxford-based manufacturer of high-field magnets. In 2005, Varian bought Polymer Laboratories, a speciality polymer analysis and manufacturing company. In 2006, Varian bought Ion Spec, an FTMS (Fourier Transform Mass Spectrometry) manufacturing company. In 2007, Varian, Inc. bought Analogix, Inc., a company specializing in flash chromatography. In 2008, Varian bought Oxford Diffraction, a British company specializing in X-ray diffraction equipment. On 27 July 2009, Agilent Technologies announced it would buy Varian Inc, for $1.5 Billion. On 14 October 2014, Agilent made the strategic decision to close its NMR business. Agilent entered the NMR business in 2010, with the acquisition of Varian. Several former Varian engineers have continued the business through private ventures, including the probe department spawning the company PhoenixNMR and the software being made open source.
Sources: en.wikipedia.org
The risk of having a myocardial infarction increases with older age, low physical activity, and low socioeconomic status. Heart attacks appear to occur more commonly in the morning hours, especially between 6 am and noon. Evidence suggests that heart attacks are at least three times more likely to occur in the morning than in the late evening. Shift work is also associated with a higher risk of MI. One analysis has found an increase in heart attacks immediately following the start of daylight saving time. Women who use combined oral contraceptive pills have a modestly increased risk of myocardial infarction, especially in the presence of other risk factors. The use of non-steroidal anti-inflammatory drugs (NSAIDs), even for as short as a week, increases risk. Endometriosis in women under the age of 40 is an identified risk factor. Patients with intravenous devices (such as a PICC line, Central Venous Catheter, and ECMO, among others) have an increased risk of DVT and thrombosis, therefore increasing the risk of a myocardial infarction and other problems caused by blood clots such as strokes. Air pollution is also an important modifiable risk. Short-term exposure to air pollution such as carbon monoxide, nitrogen dioxide, and sulfur dioxide (but not ozone) has been associated with MI and other acute cardiovascular events. For sudden cardiac deaths, every increment of 30 units in Pollutant Standards Index correlated with an 8% increased risk of out-of-hospital cardiac arrest on the day of exposure. Extremes of temperature are also associated.
Production of instant tea can be broken down into six main steps: selection of raw materials, extraction, aroma stripping, tea cream processing, concentration, and drying. Selection of tea leaves is done with the best interests of both the manufacturer and end user. Because of certain legal restrictions in tea producing countries, it is most cost effective for manufacturers to use fermented, undried black leaves, as they do not have to pass through public auctions and are therefore cheaper. Quality is not sacrificed, as research has been done to show that this type of leaf has similar flavor when compared to dried, black leaves. Extraction is done with two goals in mind: yield of tea solids extracted from the leaf, and concentration of the extract solution. Research has shown that tea leaf solubles in a column extractor can be described in a system of three components, each which obey a first-order solution law. The explanation given for why the soluble compounds fall into any of these three categories is based on how accessible they are. The instantly soluble compounds are likely to be right on the surface of the leaf, which is why they are the first to be obtained. The rapidly soluble components are thought to be from the inside of the leaves, where broken cell structures slow both the rate of solvent entering as well as solute leaving. The slowest soluble compounds are expected to have either high molecular mass, which would take longer to move through the cell matrices of the leaves, or products formed during hydrolysis over the course of the extraction.
Cardio-arrhythmia is a common side effect of diabetic patients and the anti-inflammatory effects of gingerol suppressed the risks by lowering blood glucose levels in-vivo. The anti-oxidant properties of [6]-gingerol has been considered as a defense against Alzheimer’s. A study observed the molecular mechanisms responsible for the protection against DNA fragmentation and mitochondrial membrane potential deterioration of cells which suggests a neuroprotective support of gingerol. This study indicates that ginger up-regulates glutathione production in cells, including nerve cells, through anti-oxidative properties which decreases the risk of Alzheimer's in human neuroblastoma cells and mouse hippocampal cells. While many studies suggest the low risk of using ginger phytochemicals to combat oxidation damage to cells, there are a few studies that suggest potential genotoxic effects. In one study too high of a dose to human hepatoma cells resulted in DNA fragmentation, chromosomal damage and organelle membrane instability which could result in apoptotic behavior. There are some pro-oxidant behaviors to gingerol compounds when the concentration reaches high levels although also considered, in normal conditions these phytochemicals observed have anti-inflammatory and anti-oxidant qualities. In another study [6]-Gingerol notably inhibited the metabolic rate of rats when given an intraperitoneal injection which induced a hypothermic reaction though, when consumed orally in excess there were no changes in body temperature.
Sources: en.wikipedia.org
It is normally kept frozen, desiccated, and away from light, with brief warming to room temperature before opening to limit condensation. Repeated freeze-thaw cycles are avoided because they stress the peptide. Once in solution, the material is held cold and used promptly.
Mass spectrometry gives the observed molecular mass, which is compared with the calculated value for the expected sequence. Reversed-phase chromatography shows retention behaviour and main peak purity. Peptide mapping adds sequence-level confirmation when the question requires it.
Typical entries include appearance, chromatographic purity as area percent, observed mass, water or residual solvent content, and the analytical methods used. The document reflects the lot tested and the laboratory that performed the work. It does not by itself establish that the delivered vial matches the tested lot.
Solid material is normally kept frozen at about -20 degrees Celsius, desiccated and protected from light. Solutions are held cold and used within a defined window because degradation products accumulate over time.